A number of other brokerages also recently commented on CYAD. Zacks Investment Research raised CELYAD SA/ADR from a hold rating to a buy rating and set a $29.00 price objective for the company in a research report on Tuesday, October 23rd. HC Wainwright reaffirmed a buy rating and issued a $46.00 price target on shares of CELYAD SA/ADR in a report on Monday, November 12th. Finally, Piper Jaffray Companies lowered their price target on CELYAD SA/ADR to $51.00 and set an overweight rating for the company in a report on Monday, November 12th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $44.20.
Shares of CELYAD SA/ADR stock opened at $23.41 on Tuesday. CELYAD SA/ADR has a one year low of $20.54 and a one year high of $48.20. The stock has a market cap of $210.28 million, a PE ratio of -6.61 and a beta of 1.35.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN boosted its holdings in CELYAD SA/ADR by 1,109.0% in the third quarter. Wells Fargo & Company MN now owns 6,045 shares of the company’s stock valued at $160,000 after purchasing an additional 5,545 shares in the last quarter. Victory Capital Management Inc. lifted its stake in CELYAD SA/ADR by 2.8% in the third quarter. Victory Capital Management Inc. now owns 621,162 shares of the company’s stock valued at $16,374,000 after buying an additional 17,160 shares during the last quarter. Millennium Management LLC purchased a new stake in CELYAD SA/ADR in the second quarter valued at approximately $582,000. Finally, Stanley Laman Group Ltd. purchased a new stake in CELYAD SA/ADR in the second quarter valued at approximately $1,145,000. 7.45% of the stock is owned by hedge funds and other institutional investors.
About CELYAD SA/ADR
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.
Recommended Story: Closed-End Mutual Funds (CEFs)
Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.